Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom by Kearsley-Fleet L et al.
Concise report doi:10.1093/rheumatology/key306
Use and effectiveness of rituximab in children and
young people with juvenile idiopathic arthritis in a
cohort study in the United Kingdom
Lianne Kearsley-Fleet 1, Sunil Sampath1, Liza J. McCann2, Eileen Baildam2,
Michael W. Beresford 2,3, Rebecca Davies1, Diederik De Cock1, Helen
E. Foster4,5, Taunton R. Southwood6, Wendy Thomson7,8, Kimme L. Hyrich 1,8
and the Biologics for Children with Rheumatic Diseases (BCRD) study
Abstract
Objectives. Rituximab (RTX) may be a treatment option for children and young people with JIA, although it is not
licensed for this indication. The aim of this study was to describe RTX use and outcomes among children with JIA.
Methods. This analysis included all JIA patients within the UK Biologics for Children with Rheumatic Diseases study
starting RTX. Disease activity was assessed at RTX start and at follow-up. The total number of courses each patient
received was assessed. Serious infections and infusion reactions occurring following RTX were reported.
Results. Forty-one JIA patients starting RTX were included, the majority with polyarthritis: polyarthritis RF negative
[n= 14 (35%)], polyarthritis RF positive [n= 13 (33%)] and extended oligoarthritis [n= 9 (23%)]. Most were female (80%)
with a median age of 15 years [interquartile range (IQR) 1216] and a median disease duration of 9 years (IQR 511). The
median improvement in the clinical Juvenile Arthritis Disease Activity Score (cJADAS; three-variable 71-joint JADAS) from
RTX start was 9 units (n= 7; IQR 142). More than half reported more than one course of RTX. The median time between
each course was 219 days (IQR 198315). During follow-up, 17 (41%) patients reported switching to another biologic,
including tocilizumab (n= 8), abatacept (n= 6) and TNF inhibitor (n= 3). Three patients (7%) reported a serious infection on
RTX (rate of first serious infection 6.2/100 person-years). Four patients (10%) reported an infusion reaction.
Conclusions. This real-world cohort of children with JIA, the majority with polyarticular or extended oligoarticular JIA,
showed RTX may be an effective treatment option for children who do not respond to TNF inhibitor, with a low rate of
serious infections on treatment.
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Rheumatology key messages
. Rituximab is used in children with JIA who have not responded to other therapies.
. Rituximab may be an effective treatment option for many ILAR categories of JIA.
. The rate of serious infection and the number of infusion reactions in JIA were low.
Introduction
JIA is the most common inflammatory rheumatic condition
in childhood. It encompasses seven ILAR subtypes that
differ in presentation and disease course [1]. Selective
peripheral B cell depletion using rituximab (RTX) is a rela-
tively recent advancement and an effective treatment
approved for RA [2]. Although not licensed in JIA, it is
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considered a potential treatment option, particularly in RF-
positive patients where TNF inhibitor (TNFi) treatment is
ineffective or not tolerated [3]. In RA, each course of RTX
consists of two 1000 mg i.v. infusions given 2 weeks apart,
with further courses considered after 24 weeks [4]. The
convenience of infrequent dosing, compared with other
biologics, makes it an appealing therapeutic option in
children.
There remains a question about which, if any, children
may benefit from treatment with RTX. There are no clinical
trial data for RTX in JIA. One observational study in 55
patients with severe JIA non-responsive to TNFi showed
RTX (two courses of four weekly 375 mg/m2 i.v. infusions
24 weeks apart) to be effective, with 70% of patients
achieving an ACR paediatric 70% response after
48 weeks [5]. The remaining evidence supporting RTX ef-
fectiveness consists of case reports or small case series,
predominantly in adults with JIA [610]. There is evidence
in RA that RTX may be more effective in RF-positive pa-
tients [11]. Whether this is also true for patients with JIA is
currently unknown. The aim of this current analysis was to
describe RTX use and effectiveness in a national cohort of
children and young people with JIA.
Methods
Participants were from the Biologics for Children with
Rheumatic Diseases (BCRD) study [12], an ongoing na-
tional prospective observational cohort study established
in 2010. The aim of the BCRD is to nationally monitor the
effectiveness and safety of non-etanercept biologics in
children and young people with JIA in routine clinical
care in the UK. Children starting a non-etanercept bio-
logic, regardless of prior biologic exposure, are recruited.
Recruitment is recommended nationally [3], but not man-
datory. Ethics approval for the BCRD was granted by the
North West 7 Research Ethics Committee  Greater
Manchester Central Ethics Committee. Patient or parent
written informed consent was obtained as per the
Declaration of Helsinki. Additional ethical approval to ana-
lyse these data was not required.
At registration into the BCRD, data are collected by the
treating physician or affiliated clinical research nurse on
patient demographics, disease features, disease activity
including the JIA core outcome variables [13], past and
current anti-rheumatic therapies and other medications.
Follow-up data are collected at 6 months and 1 year,
then annually, including any medication changes, current
disease activity and occurrence of adverse events. When
a patient starts a subsequent biologic after initial registra-
tion, additional data on disease activity at the start of the
new therapy and after 6 months are requested in addition
to the routine study follow-up data.
This analysis included all children from the BCRD who
ever received RTX from 1 January 2010 through 31
January 2018. Disease activity measures recorded after
approximately 6 months following the first RTX course
were identified; a range of 412 months was allowed to
account for variable timing of follow-ups. In addition, the
three-variable 71-joint clinical Juvenile Arthritis Disease
Activity Score (cJADAS) was calculated where data were
available [14]. The change in core outcome variables and
cJADAS was assessed regardless of whether patients had
received additional courses of RTX or another biologic.
The change in disease activity was assessed using the
Wilcoxon matched-pairs signed-rank test. Doses of RTX
received within 61 days of the previous dose were classi-
fied as part of the same course. The total number of RTX
courses a patient received was determined. Further RTX
courses received after an intervening alternative biologic
drug were not included in the total (n= 1).
Patients were considered exposed (on drug) from each
RTX infusion for 270 days or until the last study follow-up,
31 January 2018 (cut-off date), whichever came first.
Exposure time for the first serious infection was censored
at the time of the first serious infection. Rates of serious
infection were calculated per 100 person-years of expos-
ure [95% confidence intervals (CIs)]. Randomized con-
trolled trials define infusion reactions in adults as any
event occurring within 24 h of receiving RTX [2, 15]. The
same definition was used in this analysis. Stata version
13 (StataCorp, College Station, TX, USA) was used to
perform all analyses [16].
Results
Of 834 biologic-treated patients, 41 (5%) had been
exposed to RTX at some point—19 at the point of first
registration and 22 as a subsequent biologic after regis-
tration. The reason for starting RTX was mostly inefficacy
of previous therapy (62%) (Table 1). Overall, 80% were
female, with a median age at the start of RTX therapy of
15 years [interquartile range (IQR) 1216] and a median
disease duration of 9 years (IQR 511). The majority of
the patients had polyarthritis: polyarthritis RF negative
[n= 14 (35%)], polyarthritis RF positive [n= 13 (33%)] or
extended oligoarthritis [n= 9 (23%)]. Most patients
(n= 40) had exposure to at least one biologic before start-
ing RTX: 29% exposed to one, 39% exposed to two and
29% exposed to at least three. All patients with prior bio-
logic exposure had received TNFi, 23% tocilizumab and
20% abatacept. Only 34% were on concomitant DMARD
therapy, predominantly methotrexate (Table 1).
Twenty-nine patients (71%) had disease activity data
available at baseline and follow-up. At the start of RTX
the median active joint count was 3 (IQR 17), the
median Childhood HAQ score was 1.2 (IQR 0.11.9) and
the median cJADAS was 15 (IQR 818) (Table 2). At
follow-up, disease activity had improved; the median
change in active joint count was 1 (IQR 4 to 0;
P< 0.05) and the median change in cJADAS was 9
units (IQR 14 to 2), although data availability on some
variables were limited. Of these patients, one-quarter
(n= 7) had received additional RTX courses and four pa-
tients had received another biologic prior to the follow-up
assessment.
Of the patients with dose data available (n= 34), the
median RTX dose at the start of therapy was 1000 mg
(IQR 9001000). The majority of patients [n= 36 (88%)]
received two doses of RTX in each course, of which
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58% (n= 21) received 1000 mg for both doses. More than
half of the patients reported more than one course of RTX:
17 (41%) had one, 12 (29%) had two, 7 (17%) had three
and 5 (12%) had four or more. The median number of days
between each course was 219 (IQR 198315). Thirty-eight
patients had follow-up recorded in the BCRD following
their last recorded dose of RTX, with a median of
177 days (IQR 109398). Forty-five per cent of those
(n= 17) reported switching from RTX to another biologic,
predominantly due to inefficacy (67%), after a median time
of 178 days (IQR 133306). Eight patients started tocilizu-
mab (47%), six patients started abatacept (35%) and
three patients started TNFi (18%). Eight of these patients
switched after only one RTX course (47%), four after two
(24%) and five after three or more courses (29%).
There was a total available exposure time on RTX ther-
apy of 51 person-years. Three (7%) patients experienced
a serious infection during this time; the rate of first serious
infections was 6.2 per 100 person-years (95% CI 2.0, 19).
One patient experienced a further infection on RTX; the
rate of all serious infections was 7.8 per 100 person-years
(95% CI 2.9, 21). All serious infections occurred within a
range of 14115 days following the most recent RTX infu-
sion. Four (10%) patients experienced an infusion reac-
tion. In all cases these reactions were mild, with no patient
experiencing an anaphylactic response.
Discussion
This is one of the largest observational studies describing
RTX use and effectiveness in children and young people
with JIA. Since 2010, 5% of patients in this national cohort
have been exposed to RTX. As per the current 2015
National Health Service England guidelines for biologic
therapies in the treatment of JIA, the majority of these
patients started RTX therapy after failure of a TNFi [3].
However, despite these guidelines suggesting RTX be
considered for RF-positive polyarthritis, based on evi-
dence from RA studies [11], this ILAR category repre-
sented only one-third of patients treated. Unfortunately,
within the current study, the total number of patients
with polyarthritis was too small to form any conclusions
regarding differential benefits by antibody status.
The majority of patients reported received two 1000 mg
doses of RTX within each course, in accordance with
European licencing indications for adults with RA [4].
Data were unavailable on body surface dose given, only
data on the dose received was available. During the avail-
able follow-up, more than half the patients received at
least two courses of RTX, with a median interval between
each course of 7 months. Again, this is in line with the
European guidelines for adults with RA and suggests that
a benefit was received following the first course in many
patients. A limitation of this study is that the reason pa-
tients received additional doses were unknown (whether
due to worsening disease symptoms or a planned re-
treatment).
Only one-third of patients reported receiving concomi-
tant DMARD therapy when starting RTX treatment. The
reasons for this low proportion are unknown. Overall, dis-
ease activity across a wide range of core outcome vari-
ables improved following RTX treatment. However, within
the period of follow-up available, almost half of the pa-
tients reported switching to another biologic therapy,
most following only one or two courses, suggesting that
RTX, while effective in some patients, was not considered
effective in others.
The rate of first serious infection in this analysis was
slightly higher compared with rates reported in children
and young people with JIA treated with first-line etaner-
cept (6.2 vs 4.8 per 100 person-years), although the 95%
CIs do overlap [17]. It is possible that, due to the second-
line nature of the therapy, the patients starting RTX were
fundamentally different, i.e. older (median age 15 vs
11 years) with longer disease duration (9 vs 3 years).
Thus they may have more comorbidities, higher total
steroid exposure or poorer disease activity, function or
well-being compared with patients starting first-line
TABLE 1 Baseline characteristics of 41 patients with JIA
at the start of RTX therapy
Characteristics RTX patients
Total number of patients 41
Female, n (%) 33 (80)
Age, median (IQR), years 15 (1216)
Disease duration, median (IQR),
yearsa
9 (511)
ILARa n (%)
Systemic 
Oligoarticular, persistent 2 (5)
Oligoarticular, extended 9 (23)
Polyarticular RF negative 14 (35)
Polyarticular RF positive 13 (33)
Psoriatic 1 (3)
Enthesitis related 1 (3)
Undifferentiated 
Previous biologic exposure 40 (98)
Number of previous biologics, n (%)
0 1 (2)
1 12 (29)
2 16 (39)
53 12 (29)
If yes, which class of biologic, n (%)
TNFi 40 (100)
IL-6 pathway inhibitor
(tocilizumab)
9 (23)
T cell co-stimulation blocker
(abatacept)
8 (20)
Concurrent DMARDs 14 (34)
Ever glucocorticoids 40 (98)
RTX start reasonb, n (%)
Inadequate response/inefficacy
to previous drug
24 (62)
Intolerance/adverse events on
previous drug
5 (13)
Intolerance and inadequate
response
6 (15)
Adherence issues with prior
drug(s)
4 (10)
aData missing in one patient. bData missing in two patients.
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etanercept. The rate of serious infection observed in the
current analysis was similar to those seen in RA in both a
randomized controlled trial (RCT) [2] and a cohort study
[18]. In addition, four (10%) patients experienced an infu-
sion reaction within 24 h of a RTX infusion. Infusion reac-
tions are common in adults with RA receiving RTX and
may potentially be life threatening [19]. Two previous
RCTs of adults with RA found 2938% of RTX-treated
patients experienced an infusion reaction, compared
with 1823% of the placebo-treated patients [2, 15].
However, reporting of infusion reactions in the current
study required the clinician to perceive that it was serious
enough to record in the rheumatology record (in addition
to the hospital record of the infusion itself) and also report
to the study, which is likely to explain the differences be-
tween the two study designs.
The BCRD study is the UK’s largest cohort of JIA pa-
tients starting a non-etanercept biologic therapy.
Registration into the study is highly encouraged [3] and
therefore the numbers reported in this analysis are likely to
represent a majority of RTX-treated patients in the UK.
However, JIA is a rare disease with 20% of patients
starting a biologic therapy [20], consequently the propor-
tion of patients who may be considered for RTX will be
even lower. As disease activity at the start of RTX therapy
in patients already registered had to be additionally re-
quested, rather than the mandatory nature of those
newly registering, there were missing data. The limited
patient numbers and amount of missing data within the
dataset means that all patients were assessed at follow-
up, regardless of additional treatment, and factors asso-
ciated with good response could not be investigated.
Multiple imputation, a method usually applied to account
for missing data, could not be used on such a small
number of patients.
In this real-world cohort of children and young people
with JIA being treated with non-etanercept biologic ther-
apy, 5% of patients across many ILAR categories have
reported exposure to RTX therapy. Dosing was consistent
with current guidelines for use in adults with RA, as no
paediatric JIA dose has been studied. More than half of
the patients report using RTX for more than one course,
indicating potential benefit, with similar improvements in
disease activity measures observed. These data are reas-
suring, but ultimately patients with JIA deserve a clinical
trial of RTX therapy to establish clear efficacy and safety
of the therapy, as well as indicating in which ILAR cate-
gories RTX therapy may be most effective. As patients
continue to be followed within the BCRD study, real-
world effectiveness can continue to be assessed.
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